Treatment of hepatitis C virus and HIV coinfection: the road less traveled.
The use of HAART for HIV infection has significantly reduced morbidity and mortality secondary to AIDS-related opportunistic infections. In hepatitis C virus (HCV)-HIV-coinfected patients, progression to AIDS, cirrhosis, and liver failure from HCV infection has become an important issue. Liver disease caused by chronic HCV infection has become the second leading cause of death in some HIV-infected populations. HIV infection is not a contraindication to HCV infection therapy. Several clinical studies have borne out that HCV infection can be safely and successfully treated in HIV-HCV-coinfected patients. These patients should be evaluated and offered anti-HCV treatment as clinically indicated.
Jones
J S
JS
Cabrini Medical Center, New York, USA.
Dieterich
D T
DT
D023241:Antiretroviral Therapy, Highly Active; D019468:Disease Management; D004359:Drug Therapy, Combination; D004496:Education, Continuing; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D015995:Prevalence; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin